City
Epaper

Serbia to receive additional 2 million doses of Sputnik V COVID-19 vaccine

By ANI | Published: January 06, 2021 8:15 PM

The Russian Direct Investment Fund (RDIF) and Serbia on Wednesday signed an agreement to supply 2 million doses of Sputnik V to the country.

Open in App

The Russian Direct Investment Fund (RDIF) and Serbia on Wednesday signed an agreement to supply 2 million doses of Sputnik V to the country.

According to an official statement, "The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) and the Government of Serbia announce the agreement to supply 2 million doses of Sputnik V, the world's first registered vaccine against coronavirus, to the country."

Meanwhile, the vaccination against coronavirus with Sputnik V has started in Serbia on Wednesday.

"The first batch of the vaccine was delivered to Serbia on December 30. The use of Sputnik V vaccine in Serbia was authorized without conducting additional local clinical trials," read the statement.

It further said, "The agreement between RDIF and the Government of Serbia will enable the vaccination of 1 million people. The supplies will help Serbia secure a diversified portfolio of vaccines against coronavirus. Deliveries will be facilitated by RDIF's international partners in India, China, South Korea and other countries."

"Serbia is a long-standing partner of Russia and we support the decision of the Government of the country to use Sputnik V as an efficient tool in the fight against coronavirus. The vaccine is based on a well-studied platform of human adenoviral vectors with a proven safety track record. As Serbia has already launched vaccination against the novel coronavirus infection the agreement is aimed at ensuring a diversified vaccine portfolio for the country providing additional options to speed up vaccination and protect the population as soon as possible," said Kirill Dmitriev, CEO of the RDIF.

Sputnik V, the world's first COVID-19 vaccine, is 91.4 per cent effective according to the results of the third and final control point analysis of data of Phase III clinical trials in Russia obtained 21 days after administering the first dose to volunteers, the official statement noted.

Meanwhile, the world COVID-19 caseload has crossed 86 million cases, as per the latest updates by Johns Hopkins University.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Russian Direct Investment FundJohns Hopkins UniversityJohn hopkinsa universityCenter for systems science and engineeringJohns hopkins university centerNational center of excellenceJohns hopkins university school of medicineHopkinsKirill dmitriev
Open in App

Related Stories

HealthPoor sense of smell may be linked to depression in older people : Study

TechnologyDeaf mice have normal inner ear function until ear canal opens: Study

HealthPoor sense of smell linked to higher risk of depression in older adults: Study

Health1st in-ear wearable device to help decode long Covid-related brain fog

TechnologyResearchers reveal how psychedelic drugs reopen critical periods for social learning

International Realted Stories

InternationalSeven dead in attack on Russian police post in the North Caucasus

InternationalIsrael's attacks on Gaza a collective punishment: Egyptian PM

InternationalBaloch rights activist Mahrang Baloch highlights exploitation faced by women in Balochistan

InternationalPakistan: Abducted South Waziristan judge reaches home safely after being recovered 'unconditionally'

International"21 of our ships...protecting international shipping": EAM Jaishankar on India's growing stature in world amid tensions in Red Sea